Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788583 | 0.83 | CYP3A4 (0.71) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| Methoxsalen SCHEMBL19168 | 0.79 | CYP3A4 (1.00) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| Methoxsalen SCHEMBL29376525 | 0.79 | CYP3A4 (1.00) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| Methoxsalen SCHEMBL2302069 | 0.79 | CYP3A4 (1.00) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| Methoxsalen SCHEMBL6142553 | 0.77 | CYP3A4 (0.97) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| SCHEMBL4262282 | 0.77 | CYP3A4 (0.65) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| SCHEMBL31232813 | 0.76 | ALDH1A1 (0.62) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| Methoxsalen SCHEMBL10572509 | 0.74 | CYP3A4 (0.84) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| SCHEMBL18788581 | 0.74 | CA9 (0.70) | CYP3A4MAOACYP1A2MAPK1CYP2C19 | |
| SCHEMBL13985912 | 0.74 | MAOA (0.68) | CYP3A4MAOACYP1A2MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-20130281652-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC | 2013-10-24 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318973-B2 | Functionalized sinapic acid and methyl sinapate | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1951260-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | Bezwada Biomedical LLC (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053794-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053794-A2 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND ABSORBABLE THEREFROM | BEZWADA BIOMEDICAL LLC (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170927-A1 | FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM | COMT, AOX1, UGT1A6 | CYP3A4 345/4885MAOA 72/4885CYP1A2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.